OCP | Overall | Cases (N = 742), age 17–52 years | Controls (N = 742), age 17–52 years | NHANES 2003–2004 (N = 1016), age 17–52 yearsd | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% >LOD | LOD | % >LOD | Median | IQR | Max | % >LOD | Median | IQR | Max | % >LOD | Median | IQR | Max | LOD | |
β-HCCH | 20.5% | 4.9 | 22.3% | <LOD | <LOD - <LOD | 371.4 | 18.8% | <LOD | <LOD - <LOD | 153.8 | 60.7% | 4.3 | 2.47–8.10 | 456 | 2.3 |
γ-HCCHc | 0.6% | 5.0 | 0.6% | <LOD | <LOD - <LOD | 5277 | 0.6% | <LOD | <LOD - <LOD | 494.4 | 0.9% | <LOD | <LOD - <LOD | 73.6 | 2.1 |
HCB | 48.5% | 4.9 | 50.0% | 1.61 | <LOD − 7.52 | 150.7 | 47.1% | <LOD | <LOD-7.20 | 40.81 | 100% | 14.0 | 10.80–17.40 | 174 | 2.2 |
Mirex | 14.9% | 4.9 | 14.6% | <LOD | <LOD - <LOD | 125.4 | 15.1% | <LOD | <LOD - <LOD | 348.2 | 26.3% | <LOD | <LOD - <LOD | 166 | 2.2 |
o,p’-DDTc | 1.4% | 4.9 | 1.6% | <LOD | <LOD - <LOD | 26.7 | 1.2% | <LOD | <LOD - <LOD | 82.9 | 5.2% | <LOD | <LOD - <LOD | 88.8 | 2.1 |
p,p’-DDT | 40.1% | 4.9 | 41.2% | <LOD | <LOD-7.1 | 126.8 | 38.9% | <LOD | <LOD-6.50 | 87.1 | 69.9% | 3.96 | 2.69–5.90 | 676 | 2.3 |
p,p’-DDE | 99.9% | 4.9 | 100% | 133.3 | 82.1-230.7 | 1882 | 99.9% | 129.7 | 78.6-233.5 | 2049 | 99.7% | 165 | 97.30–318.00 | 15,100 | 2.9 |
Oxychlordane | 51.2% | 4.9 | 54.1% | 5.3 | <LOD-10.3 | 104.8 | 48.4% | <LOD | <LOD-9.90 | 40.9 | 73.2% | 7.7 | 4.10–12.60 | 61.4 | 2.5 |
trans-nonachlor | 66.9% | 4.9 | 68.7% | 8.7 | <LOD-16.4 | 304.3 | 65.1% | 7.4 | <LOD-14.50 | 89.2 | 89.4% | 11.5 | 6.60–19.80 | 121 | 2.5 |